JP2023139233A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023139233A5 JP2023139233A5 JP2023122283A JP2023122283A JP2023139233A5 JP 2023139233 A5 JP2023139233 A5 JP 2023139233A5 JP 2023122283 A JP2023122283 A JP 2023122283A JP 2023122283 A JP2023122283 A JP 2023122283A JP 2023139233 A5 JP2023139233 A5 JP 2023139233A5
- Authority
- JP
- Japan
- Prior art keywords
- schizophrenia
- pharmaceutically acceptable
- solvate
- hydrate
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000000980 schizophrenia Diseases 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 9
- 208000028017 Psychotic disease Diseases 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 239000012453 solvate Substances 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims 6
- 229960004372 aripiprazole Drugs 0.000 claims 6
- 208000024891 symptom Diseases 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 4
- 125000006731 (C1-C8) thioalkoxy group Chemical group 0.000 claims 3
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- -1 carbamate compound Chemical class 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 206010003591 Ataxia Diseases 0.000 claims 2
- 208000024254 Delusional disease Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000036755 Schizophrenia simple Diseases 0.000 claims 2
- 208000036752 Schizophrenia, paranoid type Diseases 0.000 claims 2
- 208000036750 Schizophrenia, residual type Diseases 0.000 claims 2
- 208000019568 Shared Paranoid disease Diseases 0.000 claims 2
- 208000028810 Shared psychotic disease Diseases 0.000 claims 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000004494 ethyl ester group Chemical group 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000022610 schizoaffective disease Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025043078A JP2025090816A (ja) | 2017-11-14 | 2025-03-18 | カルバメート化合物を含む統合失調症の予防、軽減又は治療用配合物 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2017-0151253 | 2017-11-14 | ||
| KR20170151253 | 2017-11-14 | ||
| JP2020544729A JP7355747B2 (ja) | 2017-11-14 | 2018-11-13 | カルバメート化合物を含む統合失調症の予防、軽減又は治療用配合物 |
| PCT/KR2018/013769 WO2019098634A1 (ko) | 2017-11-14 | 2018-11-13 | 카바메이트 화합물을 포함하는 조현병의 예방, 경감 또는 치료용 배합물 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544729A Division JP7355747B2 (ja) | 2017-11-14 | 2018-11-13 | カルバメート化合物を含む統合失調症の予防、軽減又は治療用配合物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025043078A Division JP2025090816A (ja) | 2017-11-14 | 2025-03-18 | カルバメート化合物を含む統合失調症の予防、軽減又は治療用配合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023139233A JP2023139233A (ja) | 2023-10-03 |
| JP2023139233A5 true JP2023139233A5 (https=) | 2023-10-24 |
Family
ID=66539804
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544729A Active JP7355747B2 (ja) | 2017-11-14 | 2018-11-13 | カルバメート化合物を含む統合失調症の予防、軽減又は治療用配合物 |
| JP2023122283A Pending JP2023139233A (ja) | 2017-11-14 | 2023-07-27 | カルバメート化合物を含む統合失調症の予防、軽減又は治療用配合物 |
| JP2025043078A Pending JP2025090816A (ja) | 2017-11-14 | 2025-03-18 | カルバメート化合物を含む統合失調症の予防、軽減又は治療用配合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544729A Active JP7355747B2 (ja) | 2017-11-14 | 2018-11-13 | カルバメート化合物を含む統合失調症の予防、軽減又は治療用配合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025043078A Pending JP2025090816A (ja) | 2017-11-14 | 2025-03-18 | カルバメート化合物を含む統合失調症の予防、軽減又は治療用配合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11116751B2 (https=) |
| EP (2) | EP3711759B1 (https=) |
| JP (3) | JP7355747B2 (https=) |
| KR (1) | KR102739607B1 (https=) |
| CN (2) | CN117064892A (https=) |
| AU (1) | AU2018367733B2 (https=) |
| BR (1) | BR112020009310A2 (https=) |
| ES (1) | ES3015458T3 (https=) |
| IL (1) | IL274437B2 (https=) |
| MX (1) | MX2020004975A (https=) |
| WO (1) | WO2019098634A1 (https=) |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040127489A1 (en) * | 2002-07-29 | 2004-07-01 | David Pickar | Novel antipsychotic combination therapies and compositions useful therein |
| WO2006048771A1 (en) * | 2004-11-04 | 2006-05-11 | Addex Pharmaceuticals Sa | Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
| US7598279B2 (en) * | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| EP1921073A1 (en) * | 2006-11-10 | 2008-05-14 | Laboratorios del Dr. Esteve S.A. | 1,2,4-Triazole derivatives as sigma receptor inhibitors |
| TW200848041A (en) * | 2007-03-30 | 2008-12-16 | Otsuka Pharma Co Ltd | A medicament for treating schizophrenia comprising cilostazol |
| PL2445890T3 (pl) | 2009-06-22 | 2016-02-29 | Sk Biopharmaceuticals Co Ltd | Sposób wytwarzania estru (R)-1-arylo-2-tetrazoliloetylowego kwasu karbaminowego |
| US8404461B2 (en) | 2009-10-15 | 2013-03-26 | SK Biopharmaceutical Co. Ltd. | Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester |
| US20120035156A1 (en) * | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| WO2013131018A1 (en) | 2012-03-02 | 2013-09-06 | Zalicus Pharmaceuticals Ltd. | Biaryl inhibitors of the sodium channel |
| RU2610169C2 (ru) * | 2014-09-11 | 2017-02-08 | Общество С Ограниченной Ответственностью "Валентек" | ПРОИЗВОДНЫЕ 7-ФТОРО-8-ХЛОРО-5Н-ДИБЕНЗО[b, е][1, 4]ДИАЗЕПИНА И ИХ ПРИМЕНЕНИЕ |
| WO2016044314A1 (en) * | 2014-09-15 | 2016-03-24 | Sound Pharmaceuticals Incorporated | Methods and compositions for treating psychotic disorders |
| WO2016065586A1 (en) * | 2014-10-30 | 2016-05-06 | Merck Sharp & Dohme Corp. | Pyrazole, triazole and tetrazole orexin receptor antagonists |
| US9771335B2 (en) * | 2015-07-31 | 2017-09-26 | The Johns Hopkins University | Derivatives of rufinamide and their use in inhibtion of the activation of human voltage-gated sodium channels |
| CN108601814A (zh) * | 2015-10-16 | 2018-09-28 | 西北大学 | 用于治疗精神分裂症、双相障碍、认知损害和重度抑郁障碍的非典型抗精神病药和nmda调节剂的药物组合 |
| US11221329B2 (en) * | 2015-10-30 | 2022-01-11 | Lieber Institute, Inc. | Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity |
| KR102900173B1 (ko) * | 2016-12-14 | 2025-12-12 | 에스케이바이오팜 주식회사 | 조현병, 강박장애 및 투렛증후군으로부터 선택되는 정신증 장애의 예방, 경감 또는 치료에 있어서의 카바메이트 화합물의 용도 |
| JP7724776B2 (ja) * | 2019-11-22 | 2025-08-18 | エスケー バイオファーマスティカルズ カンパニー リミテッド | カルバメート化合物を含む経口用医薬組成物及びその製造方法 |
-
2018
- 2018-11-13 MX MX2020004975A patent/MX2020004975A/es unknown
- 2018-11-13 ES ES18878582T patent/ES3015458T3/es active Active
- 2018-11-13 CN CN202311249452.9A patent/CN117064892A/zh active Pending
- 2018-11-13 KR KR1020207013847A patent/KR102739607B1/ko active Active
- 2018-11-13 IL IL274437A patent/IL274437B2/en unknown
- 2018-11-13 US US16/763,604 patent/US11116751B2/en active Active
- 2018-11-13 BR BR112020009310-6A patent/BR112020009310A2/pt unknown
- 2018-11-13 WO PCT/KR2018/013769 patent/WO2019098634A1/ko not_active Ceased
- 2018-11-13 EP EP18878582.8A patent/EP3711759B1/en active Active
- 2018-11-13 JP JP2020544729A patent/JP7355747B2/ja active Active
- 2018-11-13 EP EP25157699.7A patent/EP4545140A3/en active Pending
- 2018-11-13 CN CN201880073904.3A patent/CN111432813B/zh active Active
- 2018-11-13 AU AU2018367733A patent/AU2018367733B2/en active Active
-
2021
- 2021-08-09 US US17/397,177 patent/US11717509B2/en active Active
-
2023
- 2023-06-15 US US18/210,215 patent/US20230321041A1/en active Pending
- 2023-07-27 JP JP2023122283A patent/JP2023139233A/ja active Pending
-
2025
- 2025-03-18 JP JP2025043078A patent/JP2025090816A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020023528A5 (https=) | ||
| RU2445095C2 (ru) | Новые фармацевтические композиции для лечения сексуальных расстройств | |
| JP2018070614A5 (https=) | ||
| CN101516840B (zh) | 取代的n-酰基苯胺及其应用方法 | |
| CN106999462B (zh) | 包含选择性s1p1受体激动剂的药物组合物 | |
| US9884872B2 (en) | Organic compounds | |
| JP2019515884A5 (https=) | ||
| JP2008508214A (ja) | 女性の性障害の治療用ピペラジン誘導体 | |
| RU2007120454A (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
| CN110169962B (zh) | 用于治疗癌症的氧烯洛尔组合物 | |
| JP2024096962A (ja) | ポネシモドを含有する医薬的組み合わせ | |
| JP2024520654A5 (https=) | ||
| JP2020523317A5 (https=) | ||
| RU2007112675A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-a]ТРИАЗОЛО[1,5-d]БЕНЗОДИАЗЕПИНА ДЛЯ ЛЕЧЕНИЯ КОГНИТИВНЫХ РАССТРОЙСТВ | |
| JP2023139233A5 (https=) | ||
| JP2020502106A5 (https=) | ||
| WO2022255790A1 (ko) | 폐섬유화증의 예방 또는 치료용 약학 제제 | |
| RU2008112181A (ru) | Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3 | |
| JP2019516722A5 (https=) | ||
| CN101605541A (zh) | 有效治疗化疗药物引起的周围神经毒性的吡咯并[1,2-a]咪唑二酮 | |
| CN115607545B (zh) | 依达拉奉在自闭症谱系障碍治疗中的应用 | |
| JP2025529240A (ja) | トリナパント、セダズリジン及びデシタビンによるｔ細胞リンパ腫の治療のための併用療法 | |
| JP2023549394A5 (https=) | ||
| WO2024010030A1 (ja) | 血中マイオスタチン低下剤 | |
| RU2020119301A (ru) | Смесь, содержащая карбаматное соединение для предотвращения, облегчения или лечения шизофрении |